| Title: |
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma |
| Authors: |
Amato, David A.; Bruckner, Howard; Guerry, DuPont IV; Ash, Arlene S.; Falkson, Geoffrey; Borden, Ernest C.; Creech, Richard H.; Savlov, Edwin D.; Cunningham, Thomas J. |
| Contributors: |
Department of Quantitative Health Sciences |
| Source: |
Investigational new drugs ; 5 ; 3 ; 293-7 |
| Publication Year: |
2022 |
| Collection: |
University of Massachusetts, Medical School: eScholarship@UMMS |
| Subject Terms: |
Adolescent; Adult; Aged; 80 and over; Antineoplastic Combined Chemotherapy Protocols; effects; Cyclophosphamide; Dactinomycin; Drug Evaluation; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Mitolactol; Semustine; Biostatistics; Epidemiology; Health Services Research |
| Description: |
In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
Link to Article in PubMed; http://dx.doi.org/10.1007/BF00175301; 3667165; http://hdl.handle.net/20.500.14038/47484; https://escholarship.umassmed.edu/qhs_pp/620; 1378765; qhs_pp/620 |
| DOI: |
10.1007/BF00175301 |
| Availability: |
https://doi.org/10.1007/BF00175301; https://hdl.handle.net/20.500.14038/47484; https://escholarship.umassmed.edu/qhs_pp/620 |
| Accession Number: |
edsbas.362FBECB |
| Database: |
BASE |